Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OncoSil Medical Ltd ( (AU:OSL) ) has issued an announcement.
OncoSil Medical reported strong early real-world clinical outcomes from Ankara Bilkent City Hospital in Türkiye, where six patients with unresectable locally advanced pancreatic cancer were treated with the OncoSil™ device alongside standard FOLFIRINOX chemotherapy. The cohort achieved one complete response, four partial responses and one stable disease case, with 83% of patients subsequently undergoing successful surgical resection with curative intent—a rate materially higher than published benchmarks for chemotherapy alone and previous OncoSil™ trial data. The company said these results underscore the potential of its device to significantly improve resection rates in a patient group that typically has limited options, bolstering its commercial strategy as it continues to drive broader international adoption and build real-world evidence to support wider clinical use.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is an Australia-based global medical device company focused on interventional oncology, developing localized radiation treatments for unresectable locally advanced pancreatic cancer. Its flagship OncoSil™ device delivers targeted intratumoural Phosphorous-32 (32P) microparticles in addition to chemotherapy, enabling higher radiation doses directly into pancreatic tumours while sparing surrounding organs. The device holds CE Mark approval, breakthrough device designation in Europe and the US, and is approved in more than 30 countries including the EU, UK, Türkiye and Israel, with commercial treatments underway across several European markets and the UK.
Average Trading Volume: 24,984
Technical Sentiment Signal: Sell
Current Market Cap: A$15.87M
For a thorough assessment of OSL stock, go to TipRanks’ Stock Analysis page.